APPLIED THERAPEUTICS

Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Second Quarter 2023 Financial Results

10 Aug 2023 07:00:44 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

22 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society

15 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency

25 May 2023 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2023 Financial Results

11 May 2023 07:00:35 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

23 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

16 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference

09 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe

04 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Third Quarter 2022 Financial Results

09 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

31 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

25 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

06 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Second Quarter 2022 Financial Results

12 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference

28 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

22 Jun 2022 22:12:40 By Nasdaq GlobeNewswire